genuine question about telehealth that I am slightly embarrassed to ask
genuine question about telehealth that I am slightly embarrassed to ask, and I want the answer with the reasoning attached rather than just the conclusion.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
ask which facility, then ask for their testing
ask which facility, then ask for their testing
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
Did they name the facility?
What concentration is on the label, and does it match what you were expecting?
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
What did the intake actually ask you?
salt forms are the recurring argument and the answer is boring
a telehealth intake that asks nothing has told you what it is
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
if a clinic will not name the facility, that is your answer
do not assume the concentration matches the branded product
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
I would not read the price difference as a quality signal.
Agreed — and the follow-up question is what the beyond-use date is based on.
shortage status changes and the whole arrangement changes with it
compounded is not generic, there is no equivalence claim
- 1Removed the staff name. Facilities and clinics can be named here;…9 comments in this branch · started by u/quiet_moderator